Commission Delegated Regulation (EU) 2020/1182 of 19 May 2020 amending, for the purposes of its adaptation to technical and scientific progress, Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)
Date: 2020-05-19
Institutions: Directorate-General for Environment, European Commission
Subjects: classification, dangerous substance, environmental protection, labelling, packaging, public health, technological change








L_2020261EN.01000201.xml










11.8.2020   


EN


Official Journal of the European Union


L 261/2








            COMMISSION DELEGATED REGULATION (EU) 2020/1182
of 19 May 2020
         
amending, for the purposes of its adaptation to technical and scientific progress, Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures
(Text with EEA relevance)


THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (1), and in particular Article 37(5) thereof,

Whereas:







(1)


Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains the list of harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to that Regulation.












(2)


Proposals to introduce harmonised classification and labelling of certain substances and to update or delete the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency (‘Agency’) pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions (2) on those proposals issued by the Committee for Risk Assessment of the Agency (RAC), as well as on the comments received from the parties concerned, it is appropriate to introduce, update or delete the harmonised classification and labelling of certain substances. Those RAC opinions are:






—


Opinion of 8 June 2018 concerning nitric acid ... %[C ≤ 70 %];










—


Opinion of 9 March 2018 concerning silicon carbide fibres (with diameter < 3 μm, length > 5 μm and aspect ratio ≥ 3:1);










—


Opinion of 8 June 2018 concerning trimethoxyvinylsilane; trimethoxy(vinyl)silane;










—


Opinion of 8 June 2018 concerning tris(2-methoxyethoxy)vinylsilane; 6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecane;










—


Opinion of 8 June 2018 concerning dimethyl disulphide;










—


Opinion of 8 June 2018 concerning granulated copper;










—


Opinion of 30 November 2018 concerning bis(N-hydroxy-N-nitrosocyclohexylaminato-O,O')copper; bis(N-cyclohexyl-diazenium-dioxy)-copper; [Cu-HDO];










—


Opinion of 14 September 2018 concerning dioctyltin dilaurate; [1] stannane, dioctyl-, bis(coco acyloxy) derivs. [2];










—


Opinion of 30 November 2018 concerning dibenzo[def,p]chrysene; dibenzo[a,l]pyrene;










—


Opinion of 9 March 2018 concerning ipconazole (ISO); (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorobenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol;










—


Opinion of 8 June 2018 concerning bis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme;










—


Opinion of 8 June 2018 concerning paclobutrazol (ISO); (2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol;










—


Opinion of 8 June 2018 concerning 2,2-bis(bromomethyl)propane-1,3-diol;










—


Opinion of 14 September 2018 concerning geraniol; (2E)-3,7-dimethylocta-2,6-dien-1-ol;










—


Opinion of 28 January 2019 concerning 2-(4-tert-butylbenzyl)propionaldehyde;










—


Opinion of 9 March 2018 concerning MCPA-thioethyl (ISO); S-ethyl (4-chloro-2-methylphenoxy)ethanethioate; S-ethyl 4-chloro-o-tolyloxythioacetate;










—


Opinion of 9 March 2018 concerning diisooctyl phthalate;










—


Opinion of 14 September 2018 concerning 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl) amino}furan-2(5H)-one; flupyradifurone;










—


Opinion of 30 November 2018 concerning thiencarbazone-methyl (ISO); methyl 4- [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)carbonylsulfamoyl]-5-methylthiophene-3-carboxylate;










—


Opinion of 9 March 2018 concerning L-(+)-lactic acid; (2S)-2-hydroxypropanoic acid;










—


Opinion of 9 March 2018 concerning 2-methoxyethyl acrylate;










—


Opinion of 8 June 2018 concerning glyoxylic acid …%;










—


Opinion of 14 September 2018 concerning sodium N-(hydroxymethyl)glycinate; [formaldehyde released from sodium N-(hydroxymethyl)glycinate];










—


Opinion of 30 November 2018 concerning potassium (oxido-NNO-azoxy)cyclohexane; cyclohexylhydroxydiazene 1-oxide, potassium salt; [K-HDO];










—


Opinion of 14 September 2018 concerning mecetronium etilsulfate; N-ethyl-N,N-dimethylhexadecan-1-aminium ethyl sulfate; mecetronium ethyl sulphate [MES];










—


Opinion of 9 March 2018 concerning (2RS)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol; mefentrifluconazole;










—


Opinion of 30 November 2018 concerning oxathiapiprolin (ISO); 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone;










—


Opinion of 14 September 2018 concerning pyrithione zinc; (T-4)-bis[1-(hydroxy-.kappa.O) pyridine-2(1H)-thionato-.kappa.S]zinc;










—


Opinion of 30 November 2018 concerning 3-chloro-4-(chloromethyl)-1-[3-trifluoromethyl)phenyl]pyrrolidin-2-one; flurochloridone (ISO);










—


Opinion of 30 November 2018 concerning 4,5-dichloro-2-octyl-2H-isothiazol-3-one; [DCOIT];










—


Opinion of 8 June 2018 concerning 2-methyl-1,2-benzothiazol-3(2H)-one; [MBIT];










—


Opinion of 30 November 2018 concerning 3-(difluoromethyl)-1-methyl-N-(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide; fluxapyroxad;










—


Opinion of 8 June 2018 concerning N-(hydroxymethyl)acrylamide; methylolacrylamide; [NMA];










—


Opinion of 15 October 2018 concerning 5-fluoro-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]-1H-pyrazole-4-carboxamide; 2’-[(RS)-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide; penflufen;










—


Opinion of 30 November 2018 concerning iprovalicarb(ISO); isopropyl [(2S)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate;










—


Opinion of 30 November 2018 concerning silthiofam (ISO); N-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide;










—


Opinion of 9 March 2018 concerning Margosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide];










—


Opinion of 8 June 2018 concerning nitric acid …%[C> 70 %];










—


Opinion of 9 March 2018 concerning octamethylcyclotetrasiloxane; [D4];










—


Opinion of 30 November 2018 concerning pirimiphos-methyl (ISO); O-[2-(diethylamino)-6-methylpyrimidin-4-yl] O,O-dimethyl phosphorothioate;










—


Opinion of 30 November 2018 concerning phosphine;










—


Opinion of 14 September 2018 concerning dichlorodioctylstannane;










—


Opinion of 30 November 2018 concerning 2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE];










—


Opinion of 30 November 2018 concerning lead;










—


Opinion of 14 September 2018 concerning 2-butoxyethanol; ethylene glycol monobutyl ether;










—


Opinion of 30 November 2018 concerning m-bis(2,3-epoxypropoxy)benzene; resorcinol diglycidyl ether;










—


Opinion of 14 September 2018 concerning tribenuron-methyl (ISO); methyl 2- [N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylcarbamoylsulfamoyl]benzoate;










—


Opinion of 8 June 2018 concerning azoxystrobin (ISO); methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate;










—


Opinion of 9 March 2018 concerning ethofumesate (ISO); (RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl methanesulfonate;










—


Opinion of 30 November 2018 concerning 2,4-dinitrophenol;










—


Opinion of 14 September 2018 concerning mesotrione (ISO); 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione;










—


Opinion of 30 November 2018 concerning octhilinone (ISO); 2-octyl-2H-isothiazol-3-one; [OIT];










—


Opinion of 14 September 2018 concerning hymexazol (ISO); 3-hydroxy-5-methylisoxazole;










—


Opinion of 30 November 2018 concerning hexythiazox (ISO); trans-5-(4-chlorophenyl)-N-cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide;










—


Opinion of 9 March 2018 concerning pymetrozine (ISO); (E)-4,5-dihydro-6-methyl-4-(3-pyridylmethylene amino)-1,2,4-triazin-3(2H)-one;










—


Opinion of 9 March 2018 concerning imiprothrin (ISO); reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate;










—


Opinion of 14 September 2018 concerning butanone oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime;










—


Opinion of 8 June 2018 concerning bis(α,α-dimethylbenzyl) peroxide;










—


Opinion of 9 March 2018 concerning branched hexatriacontane;










—


Opinion of 30 November 2018 concerning hexyl 2-(1-(diethylaminohydroxyphenyl) methanoyl)benzoate; hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate.
















(3)


With regard to the substance lead (CAS number 7439-92-1 and index numbers 082-013-00-1 (lead powder; [particle diameter < 1 mm];) and 082-014-00-7 (lead massive; [particle diameter ≥ 1 mm];)), RAC proposed in its opinion of 30 November 2018 to apply the same environmental classification to the massive and the powder form. However, in view of the lower dissolution rate of the massive form, the malleable structure of lead, the specific intentional production of the powder and the different environmental classification between massive and powder forms for existing entries in Annex VI for other metals, further assessment needs to be done by RAC on whether to apply the same environmental classification to the massive as to the powder form of lead. In addition, new scientific data has been made available suggesting that the environmental classification for the massive form as recommended in the RAC opinion might not be appropriate Therefore, the environmental classification for the massive form will not be included in Annex VI to Regulation (EC) No 1272/2008 until RAC has had the opportunity to deliver a revised opinion.












(4)


With regard to the substance 2-butoxyethanol; ethylene glycol monobutyl ether; (CAS number 111-76-2), new scientific data has been made available for the hazard class ‘acute toxicity (inhalation)’ which suggests that the classification for this hazard class as recommended in the RAC opinion, which is based on older data, might not be appropriate. Therefore, this hazard class should not be modified in Annex VI to Regulation (EC) No 1272/2008 until RAC has had the opportunity to deliver a revised opinion based on the new information, while all other hazard classes covered by the RAC opinion should be included.












(5)


Regulation (EC) No 1272/2008 should therefore be amended accordingly.












(6)


Compliance with the new or updated harmonised classifications should not be required immediately as a certain period of time is necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new or revised classifications and to sell existing stocks subject to the pre-existing regulatory requirements. That period of time is also necessary to allow suppliers sufficient time to take the actions required to ensure continuing compliance with other legal requirements following the changes made under this Regulation. Such requirements may include those set out in point (f) of Article 22(1) of Regulation (EC) No 1907/2006 of the European Parliament and of the Council (3) or those set out in Article 50 of Regulation (EU) No 528/2012 of the European Parliament and of the Council (4).












(7)


Suppliers should, however, have the possibility to apply the new classification, labelling and packaging provisions on a voluntary basis before the date of application of this Regulation. This is consistent with the approach taken under Article 61(2) of Regulation (EC) No 1272/2008,





HAS ADOPTED THIS REGULATION:



Article 1

Amendments to Regulation (EC) No 1272/2008

Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.


Article 2

Entry into force and application

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
It shall apply from 1 March 2022.
By way of derogation from the second paragraph of this Article, substances and mixtures may, before 1 March 2022 be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.




This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 19 May 2020.


For the Commission


The President

Ursula VON DER LEYEN
            





(1)  
            OJ L 353, 31.12.2008, p. 1.

(2)  The opinions are accessible via the following website: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/

(3)  Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006
         
concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1).

(4)  Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ L 167, 27.6.2012, p. 1).




ANNEX
In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:






(1)


the following entries are inserted:
















Index No




Chemical name




EC No




CAS No




Classification




Labelling




Specific Conc. Limits, M-factors and ATE




Notes






Hazard Class and Category Code(s)




Hazard statement Code(s)




Pictogram, Signal Word Code(s)




Hazard statement Code(s)




Suppl. Hazard statement Code(s)





‘007-030-00-3


nitric acid …% [C ≤ 70 %]


231-714-2


7697-37-2.


Ox. Liq. 3
Acute Tox. 3
Skin Corr. 1A


H272
H331
H314


GHS03
GHS06
GHS05
Dgr


H272
H331
H314


EUH071


Ox. Liq. 3; H272: C ≥ 65 %
inhalation: ATE = 2,65 mg/L (vapours)
Skin Corr. 1A; H314: C ≥ 20 %
Skin Corr. 1B; H314: 5 % ≤ C < 20 %


B’




‘014-048-00-5


silicon carbide fibres (with diameter < 3 μm, length > 5 μm and aspect ratio ≥ 3:1)


206-991-8


409-21-2
308076-74-6


Carc. 1B


H350i


GHS08
Dgr


H350i’


 


 


 




‘014-049-00-0


trimethoxyvinylsilane; trimethoxy(vinyl)silane


220-449-8


2768-02-7


Skin Sens. 1B


H317


GHS07
Wng


H317’


 


 


 




‘014-050-00-6


tris(2-methoxyethoxy)vinylsilane;
6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecane


213-934-0


1067-53-4


Repr. 1B


H360FD


GHS08
Dgr


H360FD’


 


 


 




‘016-098-00-3


dimethyl disulphide


210-871-0


624-92-0


Flam. Liq. 2
Acute Tox. 3
Acute Tox. 3
STOT SE 3
STOT SE 1
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H225
H331
H301
H336
H370 (upper respiratory tract, inhalation)
H319
H317
H400
H410


GHS02
GHS06
GHS08
GHS09
Dgr


H225
H331
H301
H336
H370 (upper respiratory tract, inhalation)
H319
H317
H410


 


inhalation: ATE = 5 mg/L (vapours)
oral: ATE = 190 mg/kg bw
M = 1
M = 10’


 




‘029-024-00-X


granulated copper;
[particle length: from 0,9 mm to 6,0 mm; particle width: from 0,494 to 0,949 mm]


231-159-6


7440-50-8


Aquatic Chronic 2


H411


GHS09


H411’


 


 


 




‘029-025-00-5


bis(N-hydroxy-N-nitrosocyclohexylaminato-O,O’)copper;
bis(N-cyclohexyl-diazenium-dioxy)-copper;
[Cu-HDO]


239-703-4


312600-89-8
15627-09-5


Flam. Sol. 1
Acute Tox. 4
STOT RE 2
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1


H228
H302
H373 (liver)
H318
H400
H410


GHS02
GHS07
GHS08
GHS05
GHS09
Dgr


H228
H302
H373(liver)
H318
H410


 


oral: ATE = 360 mg/kg bw
M = 1
M = 1’


 




‘050-031-00-9


dioctyltin dilaurate; [1]
stannane, dioctyl-, bis(coco acyloxy) derivs. [2]


222-883-3 [1] 293-901-5 [2]


3648-18-8 [1] 91648-39-4 [2]


Repr. 1B
STOT RE 1


H360D
H372 (immune system)


GHS08
Dgr


H360D
H372 (immune system)’


 


 


 




‘601-092-00-0


dibenzo[def,p]chrysene;
dibenzo[a,l]pyrene


205-886-4


191-30-0


Carc. 1B
Muta. 2


H350
H341


GHS08
Dgr


H350
H341


 


Carc. 1B; H350: C ≥ 0,001 %’


 




‘603-237-00-3


ipconazole (ISO);
(1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorobenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol


-


125225-28-7
115850-69-6
115937-89-8


Repr. 1B
Acute Tox. 4
STOT RE 2
Aquatic Chronic 1


H360D
H302
H373 (eyes, skin, liver)
H410


GHS08
GHS07
GHS09
Dgr


H360D
H302
H373 (eyes, skin, liver)
H410


 


oral: ATE = 500 mg/kg bw
M = 100’


 




‘603-238-00-9


bis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme


205-594-7


143-24-8


Repr. 1B


H360FD


GHS08
Dgr


H360FD’


 


 


 




‘603-239-00-4


paclobutrazol (ISO);
(2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol


-


76738-62-0


Repr. 2
Acute Tox. 4
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1


H361d
H332
H302
H319
H400
H410


GHS08
GHS07
GHS09
Wng


H361d
H332
H302
H319
H410


 


inhalation: ATE = 3,13 mg/L (dusts or mists)
oral: ATE = 490 mg/kg bw
M = 10
M = 10’


 




‘603-240-00-X


2,2-bis(bromomethyl)propane-1,3-diol


221-967-7


3296-90-0


Carc. 1B
Muta. 1B


H350
H340


GHS08
Dgr


H350
H340’


 


 


 




‘603-241-00-5


geraniol;
(2E)-3,7-dimethylocta-2,6-dien-1-ol


203-377-1


106-24-1


Skin Sens. 1


H317


GHS07
Wng


H317’


 


 


 




‘605-041-00-3


2-(4-tert-butylbenzyl)propionaldehyde


201-289-8


80-54-6


Repr. 1B


H360Fd


GHS08
Dgr


H360Fd’


 


 


 




‘607-738-00-8


MCPA-thioethyl (ISO);

S-ethyl (4-chloro-2-methylphenoxy)ethanethioate; S-ethyl 4-chloro-o-tolyloxythioacetate


246-831-4


25319-90-8


Acute Tox. 4
STOT RE. 2
Aquatic Acute 1 Aquatic Chronic 1


H302
H373 (liver)
H400
H410


GHS07
GHS08
GHS09
Wng


H302
H373 (liver)
H410


 


oral: ATE = 450 mg/kg bw
M = 10
M = 10’


 




‘607-740-00-9


diisooctyl phthalate


248-523-5


27554-26-3


Repr. 1B


H360FD


GHS08
Dgr


H360FD’


 


 


 




‘607-741-00-4


4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one; flupyradifurone


-


951659-40-8


Acute Tox. 4
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1


H302
H373 (muscle)
H400
H410


GHS07
GHS08
GHS09
Wng


H302
H373 (muscle)
H410


 


oral: ATE = 500 mg/kg bw
M = 10
M = 10’


 




‘607-742-00-X


thiencarbazone-methyl (ISO);
methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)carbonylsulfamoyl]-5- methylthiophene-3-carboxylate


-


317815-83-1


Aquatic Acute 1
Aquatic Chronic 1


H400
H410


GHS09
Wng


H410


 


M = 1000
M = 1000’


 




‘607-743-00-5


L-(+)-lactic acid;
(2S)-2-hydroxypropanoic acid


201-196-2


79-33-4


Skin Corr. 1C
Eye Dam. 1


H314
H318


GHS05
Dgr


H314


EUH071’


 


 




‘607-744-00-0


2-methoxyethyl acrylate


221-499-3


3121-61-7


Flam. Liq. 3
Muta. 2
Repr. 1B
Acute Tox. 3
Acute Tox. 4
Skin Corr. 1C
Eye Dam. 1
Skin Sens. 1


H226
H341
H360FD
H331
H302
H314
H318
H317


GHS02
GHS05
GHS06
GHS08
Dgr


H226
H341
H360FD
H331
H302
H314
H317


EUH071


inhalation: ATE = 2,7 mg/L (vapours)
oral: ATE = 404 mg/kg bw’


 




‘607-745-00-6


glyoxylic acid …%


206-058-5


298-12-4


Eye Dam. 1
Skin Sens. 1B


H318
H317


GHS05
GHS07
Dgr


H318
H317


 


 


B’




‘607-746-00-1


sodium N-(hydroxymethyl)glycinate;
[formaldehyde released from sodium N-(hydroxymethyl)glycinate]


274-357-8


70161-44-3


Carc. 1B
Muta. 2
Acute Tox. 4
Acute Tox. 4
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1


H350
H341
H332
H302
H335
H315
H319
H317


GHS08
GHS07
Dgr


H350
H341
H332
H302
H335
H315
H319
H317


 


inhalation: ATE = 3 mg/L (dusts or mists)
oral: ATE = 1100 mg/kg bw


8
9’




‘611-181-00-6


potassium (oxido-NNO-azoxy)cyclohexane;
cyclohexylhydroxydiazene 1-oxide, potassium salt;
[K-HDO]


-


66603-10-9


Flam. Sol. 1
Acute Tox. 3
STOT RE 2
Skin Irrit. 2
Eye Dam. 1
Aquatic Chronic 2


H228
H301
H373 (liver)
H315
H318
H411


GHS02
GHS06
GHS08
GHS05
GHS09
Dgr


H228
H301
H373 (liver)
H315
H318
H411


 


oral: ATE = 136 mg/kg bw’


 




‘612-294-00-3


mecetronium etilsulfate;

N-ethyl-N,N-dimethylhexadecan-1-aminium ethyl sulfate;
mecetronium ethyl sulphate;
[MES]


221-106-5


3006-10-8


Skin Corr. 1
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1


H314
H318
H400
H410


GHS05
GHS09
Dgr


H314
H410


EUH071


M = 100
M = 1000’


 




‘613-331-00-6


(2RS)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol;
mefentrifluconazole


-


1417782-03-6


Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H317
H400
H410


GHS07
GHS09
Wng


H317
H410


 


M = 1
M = 1’


 




‘613-332-00-1


oxathiapiprolin (ISO);
1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone


-


1003318-67-9


Aquatic Chronic 1


H410


GHS09
Wng


H410


 


M = 1’


 




‘613-333-00-7


pyrithione zinc; (T-4)-bis[1-(hydroxy-.kappa.O)pyridine-2(1H)-thionato-.kappa.S]zinc


236-671-3


13463-41-7


Repr. 1B
Acute Tox. 2
Acute Tox. 3
STOT RE 1
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1


H360D
H330
H301
H372
H318
H400
H410


GHS08
GHS06
GHS05
GHS09
Dgr


H360D
H330
H301
H372
H318
H410


 


inhalation: ATE = 0,14 mg/L (dusts or mists)
oral: ATE = 221 mg/kg bw
M = 1000
M = 10’


 




‘613-334-00-2


flurochloridone (ISO);
3-chloro-4-(chloromethyl)-1-[3-(trifluoromethyl)phenyl]pyrrolidin-2-one


262-661-3


61213-25-0


Repr. 1B
Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H360FD
H302
H317
H400
H410


GHS08
GHS07
GHS09
Dgr


H360FD
H302
H317
H410


 


oral: ATE = 500 mg/kg bw
M = 100
M = 100’


 




‘613-335-00-8


4,5-dichloro-2-octyl-2H-isothiazol-3-one; [DCOIT]


264-843-8


64359-81-5


Acute Tox. 2
Acute Tox. 4
Skin Corr. 1
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1


H330
H302
H314
H318
H317
H400
H410


GHS06
GHS05
GHS09
Dgr


H330
H302
H314
H317
H410


EUH071


inhalation: ATE = 0,16 mg/L (dusts or mists)
oral: ATE = 567 mg/kg bw
Skin Irrit. 2; H315: 0,025 % ≤ C < 5 %
Eye Irrit. 2; H319: 0,025 % ≤ C < 3 %
Skin Sens. 1A; H317: C ≥ 0,0015 %
M = 100
M = 100’


 




‘613-336-00-3


2-methyl-1,2-benzothiazol-3(2H)-one;
[MBIT]


-


2527-66-4


Acute Tox. 4
Acute Tox. 3
Skin Corr. 1C
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 2


H312
H301
H314
H318
H317
H400
H411


GHS06
GHS05
GHS09
Dgr


H312
H301
H314
H317
H410


EUH071


dermal: ATE = 1100 mg/kg bw
oral: ATE = 175 mg/kg bw
Skin Sens. 1A; H317: C ≥ 0,0015 %
M = 1’


 




‘616-228-00-4


3-(difluoromethyl)-1-methyl-N-(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide;
fluxapyroxad


-


907204-31-3


Lact.
Aquatic Acute 1
Aquatic Chronic 1


H362
H400
H410


GHS09
Wng


H362
H410


 


M = 1
M = 1’


 




‘616-230-00-5



N-(hydroxymethyl)acrylamide; methylolacrylamide; [NMA]


213-103-2


924-42-5


Carc. 1B
Muta. 1B
STOT RE 1


H350
H340
H372 (peripheral nervous system)


GHS08
Dgr


H350
H340
H372 (peripheral nervous system)’


 


 


 




‘616-231-00-0


5-fluoro-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]-1H-pyrazole-4-carboxamide; 2'-[(RS)-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide;
penflufen


-


494793-67-8


Carc. 2
Aquatic Acute 1
Aquatic Chronic 1


H351
H400
H410


GHS08
GHS09
Wng


H351
H410


 


M = 1
M = 1’


 




‘616-232-00-6


iprovalicarb (ISO);
isopropyl [(2S)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate


-


140923-17-7


Carc. 2


H351


GHS08
Wng


H351’


 


 


 




‘616-233-00-1


silthiofam (ISO);

N-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide


-


175217-20-6


STOT RE 2
Aquatic Chronic 2


H373
H411


GHS08
GHS09
Wng


H373
H411’


 


 


 




‘650-057-00-6


Margosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide]


283-644-7


84696-25-3


Aquatic Chronic 3


H412


 


H412’


 


 


 














(2)


the entries corresponding to index numbers 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616-014-00-0 and 617-006-00-X are replaced by the following entries respectively:
















Index No




Chemical name




EC No




CAS No




Classification




Labelling




Specific Conc. Limits, M-factors and ATE




Notes






Hazard Class and Category Code(s)




Hazard statement Code(s)




Pictogram, Signal Word Code(s)




Hazard statement Code(s)




Suppl. Hazard statement Code(s)





‘007-004-00-1


nitric acid …% [C > 70 %]


231-714-2


7697-37-2


Ox. Liq. 2
Acute Tox. 1
Skin Corr. 1A


H272
H330
H314


GHS03
GHS06
GHS05
Dgr


H272
H330
H314


EUH071


Ox. Liq. 2; H272: C ≥ 99 %
Ox. Liq. 3; H272: 70 % ≤ C < 99 %


B’




‘014-018-00-1


octamethylcyclotetrasiloxane;
[D4]


209-136-7


556-67-2


Repr. 2
Aquatic Chronic 1


H361f ***
H410


GHS08
GHS09
Wng


H361f ***
H410


 


M = 10’


 




‘015-134-00-5


pirimiphos-methyl (ISO);

O-[2-(diethylamino)-6-methylpyrimidin-4-yl] O,O-dimethyl phosphorothioate


249-528-5


29232-93-7


Acute Tox. 4
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1


H302
H372 (nervous system)
H400
H410


GHS07
GHS08
GHS09
Dgr


H302
H372 (nervous system)
H410


 


oral: ATE = 1414 mg/kg bw
M = 1000
M = 1000’


 




‘015-181-00-1


phosphine


232-260-8


7803-51-2


Flam. Gas 1
Press. Gas
Acute Tox. 1
Skin Corr. 1B
Aquatic Acute 1


H220
H330
H314
H400


GHS02
GHS04
GHS06
GHS05
GHS09
Dgr


H220
H330
H314
H400


 


inhalation:
ATE = 10 ppmV (gases)


U’




‘050-021-00-4


dichlorodioctylstannane


222-583-2


3542-36-7


Repr. 1B
Acute Tox. 2
STOT RE 1
Aquatic Chronic 3


H360D
H330
H372 **
H412


GHS08
GHS06
Dgr


H360D
H330
H372 **
H412


 


Repr. 1B; H360 D: C ≥ 0,03 %
inhalation: ATE = 0,098 mg/L (dusts or mists)’


 




‘050-027-00-7


2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE]


239-622-4


15571-58-1


Repr. 1B
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1


H360D
H372 (immune system)
H400
H410


GHS08
GHS09
Dgr


H360D
H372 (immune system)
H410’


 


 


 




‘082-013-00-1


lead powder; [particle diameter < 1 mm]


231-100-4


7439-92-1


Repr. 1A
Lact.
Aquatic Acute 1
Aquatic Chronic 1


H360FD
H362
H400
H410


GHS08
GHS09
Dgr


H360FD H362
H410


 


Repr. 1A; H360D: C ≥ 0,03 %
M = 1
M = 10’


 




‘603-014-00-0


2-butoxyethanol;
ethylene glycol monobutyl ether


203-905-0


111-76-2


Acute Tox. 4*
Acute Tox. 4
Skin Irrit. 2
Eye Irrit. 2


H332
H302
H315
H319


GHS07
Wng


H332
H302
H315
H319


 


oral: ATE = 1200 mg/kg bw’


 




‘603-065-00-9



m-bis(2,3-epoxypropoxy)benzene;
resorcinol diglycidyl ether


202-987-5


101-90-6


Carc. 1B
Muta. 2
Acute Tox. 3
Acute Tox. 4
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
Aquatic Chronic 3


H350
H341
H311
H302
H315
H319
H317
H412


GHS08
GHS06
Dgr


H350
H341
H311
H302
H315
H319
H317
H412


 


dermal: ATE = 300 mg/kg bw oral: ATE = 500 mg/kg bw’


 




‘607-177-00-9


tribenuron-methyl (ISO);
methyl 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylcarbamoylsulfamoyl]benzoate


401-190-1


101200-48-0


STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H373
H317
H400
H410


GHS08
GHS07
GHS09
Wng


H373
H317
H410


 


M = 100
M = 100’


 




‘607-256-00-8


azoxystrobin (ISO);
methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate


-


131860-33-8


Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1


H331
H400
H410


GHS06
GHS09
Dgr


H331
H410


 


inhalation:
ATE = 0,7 mg/L (dusts or mists)
M = 10
M = 10’


 




‘607-314-00-2


ethofumesate (ISO);
(RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl methanesulfonate


247-525-3


26225-79-6


Aquatic Acute 1
Aquatic Chronic 1


H400
H410


GHS09
Wng


H410


 


M = 1
M = 1’


 




‘609-041-00-4


2,4-dinitrophenol


200-087-7


51-28-5


Acute Tox. 3 *
Acute Tox. 3
Acute Tox. 2
STOT RE 1
Aquatic Acute 1


H331
H311
H300
H372
H400


GHS06
GHS08
GHS09
Dgr


H331
H311
H300
H372
H400


 


dermal: ATE = 300 mg/kg bw oral: ATE = 30 mg/kg bw’


 




‘609-064-00-X


mesotrione (ISO);
2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione


-


104206-82-8


Repr. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1


H361d
H373 (eyes, nervous system)
H400
H410


GHS08
GHS09
Wng


H361d
H373 (eyes, nervous system)
H410


 


M = 10
M = 10’


 




‘613-112-00-5


octhilinone (ISO);
2-octyl-2H-isothiazol-3-one; [OIT]


247-761-7


26530-20-1


Acute Tox. 2
Acute Tox. 3
Acute Tox. 3
Skin Corr. 1
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1 Aquatic Chronic 1


H330
H311
H301
H314
H318
H317
H400
H410


GHS06
GHS05
GHS09
Dgr


H330
H311
H301
H314
H317
H410


EUH071


inhalation: ATE = 0,27 mg/L (dusts or mists)
dermal: ATE = 311 mg/kg bw oral: ATE = 125 mg/kg bw
Skin Sens. 1A; H317: C ≥ 0,0015 %
M = 100
M = 100’


 




‘613-115-00-1


hymexazol (ISO);
3-hydroxy-5-methylisoxazole


233-000-6


10004-44-1


Repr. 2
Acute Tox. 4
Eye Dam. 1
Skin Sens. 1
Aquatic Chronic 2


H361d
H302
H318
H317
H411


GHS08
GHS07
GHS05
GHS09
Dgr


H361d
H302
H318
H317
H411


 


oral: ATE = 1600 mg/kg bw’


 




‘613-125-00-6


hexythiazox (ISO);

trans-5-(4-chlorophenyl)-N-cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide


-


78587-05-0


Aquatic Acute 1
Aquatic Chronic 1


H400
H410


GHS09
Wng


H410


 


M = 1
M = 1’


 




‘613-202-00-4


pymetrozine (ISO);
(E)-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one


-


123312-89-0


Carc. 2
Repr. 2
Aquatic Chronic 1


H351
H361fd
H410


GHS08
GHS09
Wng


H351
H361fd
H410


 


M = 1’


 




‘613-259-00-5


imiprothrin (ISO);
reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate


428-790-6


72963-72-5


Carc. 2
Acute Tox. 4
Acute Tox. 4
STOT SE 2
Aquatic Acute 1
Aquatic Chronic 1


H351
H332
H302
H371 (nervous system; oral, inhalation)
H400
H410


GHS08
GHS07
GHS09
Wng


H351
H332
H302
H371 (nervous system; oral, inhalation)
H410


 


inhalation: ATE = 1,4 mg/L (dusts or mists)
oral: ATE = 550 mg/kg bw
M = 10
M = 10’


 




‘616-014-00-0


butanone oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime


202-496-6


96-29-7


Carc. 1B
Acute Tox. 4
Acute Tox. 3
STOT SE 3
STOT SE 1
STOT RE 2
Skin Irrit. 2
Eye Dam. 1
Skin Sens. 1


H350
H312
H301
H336
H370 (upper respiratory tract)
H373 (blood system)
H315
H318
H317


GHS08
GHS06
GHS05
Dgr


H350
H312
H301
H336
H370 (upper respiratory tract)
H373 (blood system)
H315
H318
H317


 


dermal: ATE = 1100 mg/kg bw oral: ATE = 100 mg/kg bw’


 




‘617-006-00-X


bis(α,α-dimethylbenzyl) peroxide


201-279-3


80-43-3


Org. Perox. F
Repr. 1B
Skin Irrit. 2
Eye Irrit. 2
Aquatic Chronic 2


H242
H360D
H315
H319
H411


GHS02
GHS08
GHS07
GHS09
Dgr


H242
H360D
H315
H319
H411’


 


 


 














(3)


the entries corresponding to index numbers 601-064-00-8 and 607-693-00-4 are deleted.